{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:33:12Z","timestamp":1787067192039,"version":"build-2736575974"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.euroneuro.2023.03.009","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T04:58:16Z","timestamp":1681448296000},"page":"30-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Antidepressant efficacy of cariprazine in bipolar disorder and the role of its pharmacodynamic properties: A hypothesis based on data"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5503-0811","authenticated-orcid":false,"given":"Konstantinos N.","family":"Fountoulakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5992-8941","authenticated-orcid":false,"given":"Magdalini","family":"Ioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Tohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9006-8863","authenticated-orcid":false,"given":"Bartholomeus C.M.","family":"Haarman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4442-7412","authenticated-orcid":false,"suffix":"JR.","given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2023.03.009_bib0001","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.pnpbp.2006.06.014","article-title":"Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications","volume":"31","author":"Brugue","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2023.03.009_bib0002","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1038\/sj.mp.4001019","article-title":"Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents","volume":"7","author":"Bymaster","year":"2002","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0003","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41593-021-00971-w","article-title":"Structure-based design of a novel third-generation antipsychotic drug lead with potential antidepressant properties","volume":"25","author":"Chen","year":"2022","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0004","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1017\/S1092852913000680","article-title":"Long-term effects of cariprazine exposure on dopamine receptor subtypes","volume":"19","author":"Choi","year":"2014","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0005","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1017\/S1092852916000894","article-title":"Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine","volume":"22","author":"Choi","year":"2017","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0006","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1017\/S1461145709990344","article-title":"Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis","volume":"13","author":"Cruz","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0007","first-page":"23","article-title":"Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis","volume":"13","author":"Davis","year":"1978","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0008","first-page":"533","article-title":"Cholinergic imbalance hypotheses of psychoses and movement disorders: strategies for evaluation","volume":"1","author":"Davis","year":"1975","journal-title":"Psychopharmacol. Commun."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0009","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/cns.12867","article-title":"The novel atypical antipsychotic cariprazine demonstrates dopamine D2 receptor-dependent partial agonist actions on rat mesencephalic dopamine neuronal activity","volume":"24","author":"Delcourte","year":"2018","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1176\/appi.ajp.2015.15020164","article-title":"An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar i depression","volume":"173","author":"Durgam","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0011","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/ijnp\/pyx038","article-title":"Cariprazine exhibits anxiolytic and dopamine D3 receptor-dependent antidepressant effects in the chronic stress model","volume":"20","author":"Duric","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0012","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1176\/appi.ajp.2018.18070824","article-title":"Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study","volume":"176","author":"Earley","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0013","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bdi.12852","article-title":"Efficacy and safety of cariprazine in bipolar I depression: a double-blind, placebo-controlled phase 3 study","volume":"22","author":"Earley","year":"2020","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0014","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.psychres.2015.05.114","article-title":"Cariprazine delays ouabain-evoked epileptiform spikes and loss of activity in rat hippocampal slices","volume":"229","author":"El-Mallakh","year":"2015","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0015","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1177\/0269881120936891","article-title":"Long-term administration of cariprazine increases locus coeruleus noradrenergic neurons activity and serotonin1A receptor neurotransmission in the hippocampus","volume":"34","author":"El Mansari","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0016","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.euroneuro.2014.11.010","article-title":"The pharmacodynamic properties of lurasidone and their role in its antidepressant efficacy in bipolar disorder","volume":"25","author":"Fountoulakis","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0017","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1744-859X-10-8","article-title":"Class effect of pharmacotherapy in bipolar disorder: fact or misbelief?","volume":"10","author":"Fountoulakis","year":"2011","journal-title":"Ann. Gen. Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2023.03.009_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00406-012-0323-x","article-title":"Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry","volume":"262","author":"Fountoulakis","year":"2012","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0019","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jad.2011.04.043","article-title":"Receptor targets for antidepressant therapy in bipolar disorder: an overview","volume":"138","author":"Fountoulakis","year":"2012","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0020","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jad.2010.10.018","article-title":"Aripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysis","volume":"133","author":"Fountoulakis","year":"2011","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0021","doi-asserted-by":"crossref","first-page":"12509","DOI":"10.1038\/s41598-018-30794-y","article-title":"Binding kinetics of cariprazine and aripiprazole at the dopamine D3 receptor","volume":"8","author":"Frank","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0022","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/2045125316672136","article-title":"Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole","volume":"7","author":"Frankel","year":"2017","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0023","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1515\/REVNEURO.1993.4.1.63","article-title":"The adrenergic-cholinergic imbalance hypothesis of depression: a review and a perspective","volume":"4","author":"Fritze","year":"1993","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0024","doi-asserted-by":"crossref","first-page":"e00073","DOI":"10.1002\/prp2.73","article-title":"Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor beta-arrestin interactions","volume":"3","author":"Gao","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0025","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0893-133X(00)00087-7","article-title":"Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex","volume":"22","author":"Gessa","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0026","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1007\/s00213-016-4382-y","article-title":"Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3\/D2 receptor ligand [(11)C]-(+)-PHNO","volume":"233","author":"Girgis","year":"2016","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0027","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1176\/appi.ajp.2015.15060741","article-title":"Brexpiprazole: a new antipsychotic following in the footsteps of aripiprazole","volume":"172","author":"Goff","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0028","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1124\/mol.118.113290","article-title":"Involvement of 5-HT1A and 5-HT2A receptors but not alpha 2-adrenoceptors in the acute electrophysiological effects of cariprazine in the rat brain in vivo","volume":"94","author":"Herman","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0029","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1124\/jpet.119.259879","article-title":"The role of dopamine D3 receptor partial agonism in cariprazine-induced neurotransmitter efflux in rat hippocampus and nucleus accumbens","volume":"371","author":"Huang","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0030","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/sj.npp.1301646","article-title":"N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity","volume":"33","author":"Jensen","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0031","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00213-018-4874-z","volume":"235","author":"Kehr","year":"2018","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0032","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile","volume":"333","author":"Kiss","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0033","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.2147\/DDDT.S188760","article-title":"Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine","volume":"13","author":"Kiss","year":"2019","journal-title":"Drug. Des. Devel. Ther."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0034","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejphar.2019.04.006","article-title":"Effects of cariprazine on hERG 1A and hERG 1A\/3.1 potassium channels","volume":"854","author":"Lee","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0035","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1007\/s12035-021-02498-4","article-title":"Effect of novel antipsychotics on energy metabolism - in vitro study in pig brain mitochondria","volume":"58","author":"Luptak","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0036","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.euroneuro.2022.12.012","article-title":"The efficacy of lumateperone on symptoms of depression in bipolar I and bipolar II disorder: secondary and post hoc analyses","volume":"68","author":"McIntyre","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0037","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1111\/bph.14923","article-title":"The novel antipsychotic cariprazine stabilizes gamma oscillations in rat hippocampal slices","volume":"177","author":"Meier","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0038","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0039","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/0269881120981378","article-title":"Cariprazine modulates sleep architecture in rats","volume":"35","author":"Nyitrai","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0040","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.1038\/s41467-021-26757-z","article-title":"PharmacoSTORM nanoscale pharmacology reveals cariprazine binding on Islands of Calleja granule cells","volume":"12","author":"Prokop","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0041","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1755-5949.2009.00089.x","article-title":"Is anticonvulsant treatment of mania a class effect? Data from randomized clinical trials","volume":"17","author":"Rosa","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0042","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1037\/h0046372","article-title":"Patterns of adrenergic-cholinergic imbalance in the functional psychoses","volume":"69","author":"Rubin","year":"1962","journal-title":"Psychol. Rev."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0043","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s00213-005-2198-2","article-title":"Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder","volume":"181","author":"Seager","year":"2005","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0044","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.biopsych.2004.02.012","article-title":"Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity","volume":"55","author":"Seager","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0045","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00213-011-2343-z","article-title":"Occupancy of dopamine D(2) and D(3) and serotonin 5-HT(1)A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography","volume":"218","author":"Seneca","year":"2011","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0046","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/0165-1781(81)90067-6","article-title":"Central cholinergic-adrenergic imbalance in the regulation of affective state","volume":"5","author":"Siever","year":"1981","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0047","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1017\/S1092852917000608","article-title":"Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes","volume":"22","author":"Stahl","year":"2017","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0048","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1124\/jpet.103.052597","article-title":"Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment","volume":"306","author":"Tarazi","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0049","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jad.2013.01.022","article-title":"Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies","volume":"149","author":"Tohen","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0050","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1192\/bjp.bp.112.108357","article-title":"Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression","volume":"201","author":"Tohen","year":"2012","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0051","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/syn.21631","article-title":"Brain uptake and distribution of the dopamine D3 \/D2 receptor partial agonist [11 C]cariprazine: an in vivo positron emission tomography study in nonhuman primates","volume":"67","author":"Toth","year":"2013","journal-title":"Synapse"},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0052","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1586\/14737175.2013.853448","article-title":"Cariprazine, a new, orally active dopamine D2\/3receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression","volume":"13","author":"Veselinovi\u0107","year":"2013","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0053","doi-asserted-by":"crossref","first-page":"e07","DOI":"10.4088\/JCP.8125tx4c","article-title":"Long-term treatment of bipolar depression and other issues","volume":"71","author":"Vieta","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0054","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.4088\/JCP.8125tx3c","article-title":"Role of antidepressants in bipolar depression","volume":"71","author":"Vieta","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0055","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/JCP.0b013e3181f15849","article-title":"Treatment options for bipolar depression: a systematic review of randomized, controlled trials","volume":"30","author":"Vieta","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0056","doi-asserted-by":"crossref","first-page":"508","DOI":"10.4088\/JCP.v63n0607","article-title":"A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers","volume":"63","author":"Vieta","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0057","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1399-5618.2007.00528.x","article-title":"Norepinephrine and serotonin imbalance in the locus coeruleus in bipolar disorder","volume":"10","author":"Wiste","year":"2008","journal-title":"Bipolar Disord."},{"issue":"Suppl 5","key":"10.1016\/j.euroneuro.2023.03.009_bib0058","first-page":"40","article-title":"Atypical antipsychotics in bipolar depression: potential mechanisms of action","volume":"66","author":"Yatham","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0059","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0006-3223(94)91201-7","article-title":"Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder","volume":"35","author":"Young","year":"1994","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0060","first-page":"1342","article-title":"Adrenergic-cholinergic imbalance in affective disorders","volume":"2","author":"Yudofsky","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2023.03.009_bib0061","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.euroneuro.2021.05.001","article-title":"Do cariprazine and brexpiprazole cause impulse control symptoms? A case\/non-case study","volume":"50","author":"Zazu","year":"2021","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X23000524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X23000524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:06:07Z","timestamp":1760378767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X23000524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":61,"alternative-id":["S0924977X23000524"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2023.03.009","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antidepressant efficacy of cariprazine in bipolar disorder and the role of its pharmacodynamic properties: A hypothesis based on data","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2023.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}